Immunocore Holdings rises on EU approval of cancer therapy

Immunocore Holdings

04/04/2022 14:57

** U.S.-listed shares of Britain-based drug developer
 IMCR.O  rise 1.5% to $31.5
    ** Co says European Commission (EC) has approved its therapy
candidate for treatment of metastatic uveal melanoma, a type of
cancer which affects the eye  urn:newsml:reuters.com:*:nFWN2W20PO
    ** Drug was approved by U.S. FDA in January and regulatory
authorities in UK, Canada and Australia have accepted submission
of IMCR's marketing authorization application
    ** Stock down ~7.9% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))